Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Red blood cell distribution width (RDW) is an indicator of variation in red blood cell size. An elevated RDW has been reported to be associated with increased mortality. This study investigated the effects of erythropoiesis-stimulating agents (ESAs) and hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHDs) on RDW in predialysis patients with chronic kidney disease (CKD) and renal anemia.
We conducted a retrospective study of predialysis patients with CKD who attended the nephrology outpatient department of our hospital between January 2020 and December 2022 and who had newly initiated ESAs or HIF-PHDs for renal anemia treatment. Patients were excluded if they had received blood transfusions within 3 months of starting ESAs or HIF-PHDs, initiated dialysis during the follow-up period, or switched between ESAs and HIF-PHDs. Because baseline hemoglobin (Hb) levels differed significantly between the two groups, propensity score matching was used to compare changes in RDW at 3 and 6 months. Additionally, multivariate logistic regression analysis was conducted on all eligible patients to determine whether HIF-PHD use was independently associated with RDW reduction.
We enrolled 37 patients (mean age 69.2 ± 11.7 years, 56.8% male) in the ESAs group, and 25 patients (mean age 69.8 ± 13.8 years, 56.0% male) in the HIF-PHDs group. Propensity score matching was performed using a 0.20 caliper, yielding matched pairs of 23 patients in the ESAs group and 23 in the HIF-PHDs group. At 3 months, the change in RDW was +0.74% (interquartile range: IQR -0.76 to 3.73) in the ESAs group and -3.03% (IQR, -5.84 to -0.74) in the HIF-PHDs group. RDW was significantly reduced in the HIF-PHDs group compared with the ESAs group (p<0.001). In all enrolled patients, multivariate logistic regression analysis showed that HIF-PHDs use was an independent factor associated with RDW reduction, even after adjusting for baseline Hb and RDW (after 3 months, OR 15.2, 95% CI: 3.3–102, p<0.001; after 6 months, OR 6.4, 95% CI: 1.7–29.7, p=0.006).
In predialysis patients with CKD, initiation of renal anemia treatment with HIF-PHDs, compared with ESAs, was associated with a reduction in RDW. Further investigations are needed to determine whether HIF-PHDs affect survival outcomes through RDW reduction.
